Safety, pharmacokinetics, and biologic activity of pateclizumab, a novel monoclonal antibody targeting lymphotoxin α: results of a phase I randomized, placebo-controlled trial

Identification of CXCL13 as a marker for rheumatoid arthritis outcome using an in silico model of the rheumatic joint

(2011) Cees M. Meeuwisse et al.   ARTHRITIS AND RHEUMATISM

Lymphotoxin-αβ heterotrimers are cleaved by metalloproteinases and contribute to synovitis in rheumatoid arthritis

(2010) Judy Young et al.   CYTOKINE

Comparison of interferon   release assays and conventional screening tests before tumour necrosis factor   blockade in patients with inflammatory arthritis

(2009) J Martin et al.   ANNALS OF THE RHEUMATIC DISEASES

Targeted depletion of lymphotoxin-α–expressing TH1 and TH17 cells inhibits autoimmune disease

(2009) Eugene Y Chiang et al.   NATURE MEDICINE

Potential novel biomarkers of disease activity in rheumatoid arthritis patients: CXCL13, CCL23, transforming growth factor α, tumor necrosis factor receptor superfamily member 9, and macrophage colony-stimulating factor

(2008) Inmaculada Rioja et al.   ARTHRITIS AND RHEUMATISM

Inhibition of the lymphotoxin pathway as a therapy for autoimmune disease

(2008) Jeffrey L. Browning   IMMUNOLOGICAL REVIEWS